Clinical Studies and Case Reports

On this site you will find clinical studies with cannabis or single cannabinoids in different diseases and case reports on the use of cannabis by patients.
You may search for diseases (indications), authors, medication, study design (controlled study, open trial, case report etc.) and other criteria.

[Back to Overview]  [IACM Homepage]

TitleA prospective evaluation of delta-9-tetrahydrocannabinol as an antiemetic in patients receiving adriamycin and cytoxan chemotherapy.
Author(s)Chang AE, Shiling DJ, Stillman RC, Goldberg NH, Seipp CA, Barofsky I, Rosenberg
Journal, Volume, IssueCancer 1981;47(7):1746-51
Major outcome(s)no significant reduction of the number of vomiting, volume of emesis, degree of nausea, or duration of nausea
IndicationNausea/vomiting;Cancer;Cancer chemotherapyAbstract

A randomized, double-blind, placebo-controlled trial of oral and smoked delta-9-tetrahydrocannabinol (THC) was performed in eight patients with resected soft tissue sarcomas who received adjuvant Adriamycin and Cytoxan chemotherapy. Each patient served as his own control. Delta-9-tetrahydrocannabinol, in comparison with a placebo, did not significantly reduce the number of vomiting and retching episodes, volume of emesis, degree of nausea, or duration of nausea. In contrast to a previous report where significant antiemetic effects of THC were observed in patients receiving high-dose methotrexate, THC did not effectively reduce emesis induced by Adriamycin and Cytoxan. These findings suggest that the antiemetic properties of THC are effective only against specific chemotherapeutic drugs.

Dose(s)10mg/m2 oral, 17.4mg smoking every 3 hours
Duration (days)
Participants8 patients on adriamycin and cyclophosphamide
DesignControlled study
Type of publication
Address of author(s)
Full text

[Back to Overview]  [IACM Homepage]